peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

Vasopressin V2-selective analog · nonapeptide

Desmopressin

/des-mo-PRESS-in/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

DDAVP

Tablet, nasal, or injection depending on product

Central diabetes insipidus and selected bleeding indications are route-specific.

Find official label ↗
02

Nocdurna

Sublingual tablet

Nocturia due to nocturnal polyuria in selected adults.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Renal V2 receptor activation inserts aquaporin-2 water channels in collecting ducts; endothelial V2 signaling releases von Willebrand factor and factor VIII.Mechanism source
Labeled-use boundary
Nocturia, central diabetes insipidus, and bleeding-disorder uses belong to different products and routes; they must not be collapsed into one generic instruction set.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Boxed warning

Nocdurna carries a boxed warning for potentially life-threatening hyponatremia and requires normal baseline sodium plus scheduled monitoring.Open boxed warning

Who should avoid it

  • Hyponatremia or history of hyponatremia
  • Polydipsia
  • Use with loop diuretics or systemic/inhaled glucocorticoids for Nocdurna
  • Moderate-to-severe renal impairment for selected products
  • SIADH or fluid-overload states
Contraindications

More common effects

  • Headache
  • Hyponatremia or decreased sodium
  • Dizziness
  • Dry mouth
  • Nasal symptoms for intranasal products
Adverse reactions

Important serious risks

  • Severe hyponatremia, seizure, coma, or death
  • Fluid retention
  • Thrombotic events in selected hemostatic contexts
  • Blood-pressure changes
  • Medication errors across formulations
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

One molecule, very different jobs

Antidiuretic and hemostatic uses depend on route, formulation, and population.

Supporting source
Evidence form
Multiple approved product records
Keep in view
Ingredient-level summaries are unsafe without formulation context.
02

Sodium is the central safety variable

Fluid restriction, contraindications, and sodium monitoring reduce hyponatremia risk.

Supporting source
Evidence form
Boxed-warning regulatory evidence
Keep in view
Monitoring schedules differ by product and patient risk.
03

Sex-specific Nocdurna dosing

Women receive a lower labeled dose because clinical trials showed greater sensitivity and hyponatremia risk at the higher dose.

Supporting source
Evidence form
Product-specific trial evidence
Keep in view
This finding is specific to Nocdurna, not all desmopressin products.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Nocdurna prescribing information

    DailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements.

    Open source ↗
  2. 02Literature index
    Every PubMed result for desmopressin

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for desmopressin

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    desmopressin chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗